Pere Barba Suñol

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
In the latest recommendations for the management of chronic-phase chronic myeloid leukemia suboptimal responses have been reclassified as "warning responses." In contrast to previous recommendations current guidance advises close monitoring without changing therapy. We have identified 198 patients treated with first-line imatinib, with a warning response(More)
  • 1